Glutamate hypothesis in schizophrenia

Schizophrenia is a chronic and severe psychiatric disorder that has profound impact on an individual’s life and on society. Thus, developing more effective therapeutic interventions is essential. Over the past quarter‐century, an abundance of evidence from pharmacologic challenges, post‐mortem studi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Psychiatry and clinical neurosciences Ročník 73; číslo 5; s. 204 - 215
Hlavní autoři: Uno, Yota, Coyle, Joseph T.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Melbourne John Wiley & Sons Australia, Ltd 01.05.2019
Wiley Subscription Services, Inc
Témata:
Clinical trials
D‐serine
glutamate
Glutamatergic transmission
Glutamic acid receptors
Mental disorders
N-Methyl-D-aspartic acid receptors
Neuroimaging
Neurotransmission
N‐methyl‐d‐aspartate receptor
Schizophrenia
serine racemase
Therapeutic applications
serine racemase
D-serine
schizophrenia
N-methyl-d-aspartate receptor
glutamate
ISSN:1323-1316, 1440-1819, 1440-1819
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Schizophrenia is a chronic and severe psychiatric disorder that has profound impact on an individual’s life and on society. Thus, developing more effective therapeutic interventions is essential. Over the past quarter‐century, an abundance of evidence from pharmacologic challenges, post‐mortem studies, brain imaging, and genetic studies supports the role of glutamatergic dysregulation in the pathophysiology of schizophrenia, and the results of recent randomized clinical trials based on this evidence have yielded promising results. In this article, we review the evidence that alterations in glutamatergic neurotransmission, especially focusing on the N‐methyl‐d‐aspartate receptor (NMDAR) function, may be a critical causative feature of schizophrenia, how this contributes to pathologic circuit function in the brain, and how these insights are revealing whole new avenues for treatment development that could reduce treatment‐resistant symptoms, which account for persistent disability.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1323-1316
1440-1819
1440-1819
DOI:10.1111/pcn.12823